Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21377994 | 1.00 | ACHE (0.40) | ACHEGRIN1GRIN2ACYP11B2ELANE | |
| SCHEMBL21377979 | 1.00 | ACHE (0.40) | ACHEGRIN1GRIN2ACYP11B2ELANE | |
| SCHEMBL21396826 | 0.89 | CYP11B2 (0.38) | ACHEGRIN1GRIN2ACYP11B2ELANE | |
| SCHEMBL21396894 | 0.87 | CYP11B2 (0.39) | ACHEGRIN1GRIN2ACYP11B2ELANE | |
| SCHEMBL19909047 | 0.85 | CYP11B2 (0.38) | ACHECYP11B2ELANE | |
| SCHEMBL21378049 | 0.84 | ACHE (0.39) | ACHEGRIN1GRIN2ACYP11B2ELANE | |
| SCHEMBL23912060 | 0.84 | CYP11B2 (0.51) | CYP11B2MAOAPDE10A | |
| SCHEMBL19917611 | 0.82 | GABRA1 (0.37) | ACHE | |
| SCHEMBL21377909 | 0.82 | ELANE (0.39) | ACHEGRIN1GRIN2ACYP11B2ELANE | |
| SCHEMBL21396587 | 0.81 | CYP11B2 (0.33) | ACHEGRIN1GRIN2ACYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608333-B2 | Composition of matter for use in organic light-emitting diodes | KYULUX, INC. (JP) | 2023-03-21 | — | — | US | disclosed |
| US-20190292181-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | Kyulux North America, Inc. | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292181-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | ACHE 251/4885GRIN1 1201/4885GRIN2A 859/4885 |
| US-11608333-B2 | Composition of matter for use in organic light-emitting diodes | CRY2, SLCO1B3, NDUFV3 | ACHE 251/4885GRIN1 1201/4885GRIN2A 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.